127 related articles for article (PubMed ID: 17296530)
1. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
[TBL] [Abstract][Full Text] [Related]
2. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.
van Deventer SJ; Wedel MK; Baker BF; Xia S; Chuang E; Miner PB
Aliment Pharmacol Ther; 2006 May; 23(10):1415-25. PubMed ID: 16669956
[TBL] [Abstract][Full Text] [Related]
3. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
[TBL] [Abstract][Full Text] [Related]
4. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
7. Alicaforsen. Isis Pharmaceuticals.
Gewirtz AT; Sitaraman S
Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
[TBL] [Abstract][Full Text] [Related]
8. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
Yacyshyn BR; Schievella A; Sewell KL; Tami JA
Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080
[TBL] [Abstract][Full Text] [Related]
9. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
van Deventer SJ; Tami JA; Wedel MK
Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
Mansfield JC; Parkes M; Hawthorne AB; Forbes A; Probert CS; Perowne RC; Cooper A; Zeldis JB; Manning DC; Hawkey CJ
Aliment Pharmacol Ther; 2007 Aug; 26(3):421-30. PubMed ID: 17635377
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
Miner PB; Geary RS; Matson J; Chuang E; Xia S; Baker BF; Wedel MK
Aliment Pharmacol Ther; 2006 May; 23(10):1427-34. PubMed ID: 16669957
[TBL] [Abstract][Full Text] [Related]
13. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.
Miner P; Wedel M; Bane B; Bradley J
Aliment Pharmacol Ther; 2004 Feb; 19(3):281-6. PubMed ID: 14984374
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H
Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
[TBL] [Abstract][Full Text] [Related]
15. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
Schreiber S; Nikolaus S; Malchow H; Kruis W; Lochs H; Raedler A; Hahn EG; Krummenerl T; Steinmann G;
Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
[TBL] [Abstract][Full Text] [Related]
16. Technology evaluation: alicaforsen (Isis).
Gewirtz AT; Sitaraman SV
Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
[TBL] [Abstract][Full Text] [Related]
17. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
Yacyshyn B; Bowen-Yacyshyn MB; Shanahan W
Curr Opin Mol Ther; 1999 Jun; 1(3):332-5. PubMed ID: 11713798
[TBL] [Abstract][Full Text] [Related]
18. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
Yacyshyn BR; Bowen-Yacyshyn MB; Jewell L; Tami JA; Bennett CF; Kisner DL; Shanahan WR
Gastroenterology; 1998 Jun; 114(6):1133-42. PubMed ID: 9609749
[TBL] [Abstract][Full Text] [Related]
19. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
[TBL] [Abstract][Full Text] [Related]
20. Alicaforsen therapy in inflammatory bowel disease.
Barish CF
Expert Opin Biol Ther; 2005 Oct; 5(10):1387-91. PubMed ID: 16197343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
